Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
15. November 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies ...
Freeline to Present at the Stifel Healthcare Conference
09. November 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the...
Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. November 2022 16:01 ET
|
Freeline Therapeutics Holdings plc
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on October 31, 2022, the Company granted three newly hired employees non-statutory...
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05. Oktober 2022 16:01 ET
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory...
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
04. Oktober 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06. September 2022 17:30 ET
|
Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
09. August 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. August 2022 16:01 ET
|
Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
21. Juli 2022 07:00 ET
|
Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
10. Juli 2022 03:00 ET
|
Freeline Therapeutics
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) -- Freeline...